---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-014649"
form_type: "8-K"
ticker: "ORKA"
cik: "0000907654"
company_name: "Oruka Therapeutics, Inc."
filed_at: "2022-04-18T23:59:59+00:00"
generated_at: "2026-06-26T07:02:34.804335+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ARCA biopharma establishes Special Committee to evaluate strategic options

## Summary
- Special Committee formed to explore options for maximizing stockholder value.
- Committee includes Board Chairman Robert E. Conway (chair), Linda Grais, and Anders Hove.
- Company believes multiple opportunities exist to enhance value, but no specific deal disclosed.
- No timeline given for completion of strategic review.

## SEC filing metadata
- accession: 0001564590-22-014649
- form_type: 8-K
- ticker: ORKA
- cik: 0000907654
- company_name: Oruka Therapeutics, Inc.
- filed_at: 2022-04-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/907654/000156459022014649/0001564590-22-014649-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/907654/000156459022014649/abio-8k_20220418.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-014649
- JSON: https://secwatch.observer/filing/0001564590-22-014649.json
- Plain text: https://secwatch.observer/filing/0001564590-22-014649.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.